FDA scientists question Capricor data; Legend CEO steps down

AdComNegative

AI Analysis

Summary

FDA scientists have raised questions regarding Capricor data ahead of an advisory committee meeting, causing significant share decline. Legend CEO Ying Huang resigned, and AstraZeneca reported additional pipeline challenges.

Outcome Details

FDA scientists question Capricor data ahead of advisory committee meeting

Importance:7/10

Sentiment:

-0.80

FDAadvisory committeeregulatory concernmanagement changepipeline trouble

Related Companies

$LEGN $AZN

Read the original article

Published by BioPharma Dive on July 27, 2026 3:00 PM

Read Original